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Background: Acoustic radiation force impulse (ARFI) is a novel technique for the measurement of hepatic stiffness, which could be valuable in
clinical follow-up of patients affected by cystic ﬁbrosis liver disease (CFLD).
Methods: Seventy-ﬁve patients with suspected CFLD (35 males) underwent clinical and ultrasonographic evaluations, liver and pulmonary
function tests, ARFI investigation, and upper gastrointestinal endoscopy. Ten ARFI measurements were taken at the deep right hepatic lobe to
compute median values of Shear Wave Velocity (SWV) for each individual.
Results: SWV increased progressively from 1.02 m/s (95%, Conﬁdence Interval, CI, 0.92–1.126) in patients with no evidence of CFLD at
ultrasonography (N=16), to 1.12 (95%CI 1.049–1.19) in patients with CFLD and no signs of portal hypertension (PHT, N=23), and to 1.25
(95%CI 1.14–1.358) in those with CFLD and signs of PHT (N=28). SWV was 1.63 (95%CI 1.26–1.99) in patients with oesophageal varices
(N=8) (pb0.0001).
Conclusions: ARFI may represent an easy, fast and non-invasive tool for the clinical follow-up of patients with cystic ﬁbrosis associated liver
disease.
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In the last decade, cohort studies shed light on the magnitude
of cystic fibrosis associated liver disease (CFLD) in the natural
history of cystic fibrosis. With increased life expectancy, liver
disease came into view as a relatively frequent and early
complication of cystic fibrosis, whose detection should be
focused at the first decade of life [1–3].
CFLD is histologically characterised by hepatobiliary fibrosis,
which may lead to portal hypertension (PHT), nutritional growth
delay, and failure of liver synthetic capacity up to requiring liver
transplant [4,5].
In cross-sectional and longitudinal studies, overall prevalence
of liver disease ranged from 27% [1] to 41% [2], with diagnosis
of overt cirrhosis observed in 7.8% and 9.6%, respectively. Liverby Elsevier B.V. All rights reserved.
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synthetic liver dysfunction occurred [1,2].
Defining CFLD is highly problematic. Diagnosis is based on
abnormal biochemistry, clinical and ultrasound findings of liver
involvement (i.e., hepatomegaly and/or splenomegaly). These
findings, however, may vary over time or be absent in patients
with advanced cirrhosis [1]. Several comorbidities (e.g. infections
which occur frequently in patients with cystic fibrosis) and use of
medications can cloud the diagnosis, hence altering classic non-
invasive markers of liver disease. Currently available clinical,
biochemical and radiological methods may over or underestimate
prevalence of CFLD and, more importantly, cannot predict
severity of liver damage. Indeed, a recent cohort study found that
clinical examination, serum levels of alanine aminotransferases
(ALT), and ultrasound findings fail to predict either the presence
of liver fibrosis or the development of PHT [3]. On the contrary,
fibrosis staging on liver biopsy, whose accuracywas improved by
dual-passes, predicted the development of PHT [3]. Even so, liver
biopsy has several drawbacks including sampling error as the
histologic lesions of CFLD are unevenly distributed throughout
the liver parenchyma [1], inaccuracy of liver biopsy due to intra
and inter variability of histopathological interpretation [6], high
cost, possible risk, and health-care resource utilization. Thus,
invasive liver biopsy is poorly suited as diagnostic test for such a
prevalent condition and there is need for a continuous search for
minimally invasive, sensitive and quick means of detection of
clinically important liver disease.
Acoustic radiation force impulse (ARFI) is a method exploiting
energy in transmitted acoustic pulses to deliver a localized, precise
force sufficient inmagnitude to induce subtle tissue displacements.
The induced displacements can be tracked using conventional
ultrasonic means and are indicative of local tissue mechanical
properties: tissue stiffness and visco-elasticity. Theoretically, the
stiffer is the tissue, the faster the shear wave will be propagated [7].
Quantitative in vivo measurements of parenchymal stiffness and
shear wave velocities (SWV) have been obtained in chronic
hepatopathies including viral hepatitis [7–12] and nonalcoholic
fatty liver disease [13,14]. We recently reported preliminary data
on SWV in a sample of 40 young patients with cystic fibrosis [15].
The aim of the present study was to assess the diagnostic
performance of ARFI imaging technology integrated into a
conventional ultrasound system in detecting signs of liver disease
associated with cystic fibrosis (i.e., PHT and esophageal varices).
2. Patients and methods
Seventy-five CF patients (35 males and 40 females),
followed at the CF clinic of the Bambino Gesù Hospital
(Rome, Italy), and with suspected CFLD were consecutively
enrolled from September 2009 to October 2010.
Diagnosis of CFLD was based on the presence of either
physical, biochemical or ultrasound (US) abnormalities. Clinical
hepatomegaly was defined as an increase in liver span and
consistency, with liver edge palpable more than 2 cm below the
costal margin on the mid-clavicular line. Biochemical abnormal-
ities were defined as an increase in aminotransferase activities
above normal, at least, at 2 measurements in the last 18 monthsprior of the study. Ultrasound abnormalities included hepato-
megaly, increased and heterogeneous echogenicity of the
parenchyma, nodularity, irregular margins. Diagnosis of CFLD
at ultrasonography was done in presence of at least one ultrasound
abnormality.
The study conformed to the ethical guidelines of the 1975
Declaration of Helsinki and was approved by the Ethics
Committee of the Bambino Gesù Children's Hospital. Informed
consent was obtained from parents or responsible guardians.
Information on genotype, history of meconium ileus and
diabetes, intake of ursodeoxycholic acid (20–30 mg/kg/day) or
use of recombinant long-acting insulin were available from the
CF patient's files. No patient had history of liver synthetic
dysfunction or hepatobiliary surgery. Pancreatic state was
defined on measurement of steatorrhea (defined as absorption
less than 90% of ingested fat faecal on a three day fat balance)
or stool elastase b100 μg/gstool wight. All patients received
standard CF therapy (physiotherapy, antibiotics for pulmonary
exacerbations, pancreatic enzymes, nutritional care).
Weight and height were measured following standard
procedures. The BMI z-score was calculated using the Centre
for Disease Control growth charts [16].
On the day of the study, in all patients serum liver function
tests (ALT; Aspartate Amino Transferase, AST, γGlutamyl
Transferase, γGT), liver synthetic function (international
normalized ratio and albumin) were investigated. Patients
were negative for common hepatotropic viruses (Hepatitis A,
B, C, D, E, and G; cytomegalovirus; and Epstein-Barr virus).
Scheduled examinations included pulmonary function tests
(forced vital capacity and forced expiratory volume in 1 second,
FEV1) expressed as percentage of normal predicted values for
age and sex [17], and liver ultrasounds.
2.1. Ultrasound protocol and assessment of acoustic radiation
force impulse elastography
Ultrasound images were obtained after fasting to induce
gallbladder distension. B-mode standard ultrasonography
scanning and ARFI elastography were performed using a
Siemens S2000 (Siemens Medical, Erlangen, Germany)
equipped with 2.5- to 4-MHz transducers. Images were
reviewed by three expert pediatric radiologists (CLZ, MLD &
LM) blinded to patient's data. Hepatomegaly, increased and
heterogeneous echogenicity of the parenchyma, nodularity, and
irregular margins were investigated and coded as 0 when the
ultrasound trait was absent and as 1 if present. Coded variables
entered an empirical not validated ultrasound score of CFLD
which ranged from 0 (no ultrasound evidence of CFLD) to 4,
when all the parameters were found to be present.
PHT was defined on ultrasound in presence of splenomegaly
and/or of the following criteria such as previously reported [5]:
a mean blood velocity below 10 cm/sec at the level of the portal
trunk, presence of irregular margins and nodular pattern,
enlarged portal vein diameter (measured at the porta hepatis),
presence of portal-systemic collateral veins. Splenomegaly on
ultrasound was defined as an increase of the longitudinal length
of the spleen in relation to age [18].
Table 1
Patients' characteristics.
Patients with cystic ﬁbrosis (N=75)
Sex (M/F) 35/40
Age (years) 14.4 (12.6–16.2)
Δf508 genotype
Δf508/Δf508 19 (25.3%)
Δf508/other 34 (45.3%)
Unknown 22 (28.3%)
Meconium ileus 9 (12%)
BMI (kg/m2) 19.6 (18.7–20.4)
BMI-z score (SDS) −0.22 (−0.51–0.07)
AST (UI/L) 35 (30.2–39)
ALT(UI/L) 29.2 (32.6–39.1)
γGT(UI/L) 30.7 (15.2–46.3)
Fibrinogen (mg/l) 337 (320–355)
Albumin (mg/dl) 4.23 (4.14–4.32)
INR 1.0.9 (1.06–1.15)
FEV1 (%) 87.4 (79.7–95.1)
Treatment with UDCA 40 (53%)
Diabetes 13 [17]
Pancreatic insufficiency 60 (80%)
Chronic Pseudomonas colonization 46 (61%)
Oesophageal varices 8 (11%)
On ultrasound
Increased echogenicity 38 (53%)
Heterogeneous echogenicity 55 (76.4%)
Irregular margins 28 (39%)
Nodularity 17 (15%)
PHT 28 (37.3%)
Splenomegaly 18 (24%)
Data are expressed as mean and 95% CI between parentheses or counts and
percentage. Analysis for mutation of the genes encoding for the CF
transmembrane conductance regulator was performed in all. BMI, body mass
index; CFLD, Cystic Fibrosis Liver Disease; FEV1, Forced Expiratory Volume
at min 1; PHT=Portal HyperTension; INR, International Normalized Ratio;
UDCA, Ursodeoxycholic acid.
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Quantification mode) was performed as elsewhere described
[7]. Measurements were done on the right lobe as SWV
measured on the left lobe is significantly affected by diaphragm
respiratory movements and heart-beating [7]. The right lobe of
the liver was accessed through an intercostal space while the
patient lays in the dorsal decubitus position with the right arm
in maximum abduction. The patient was asked to suspend
breathing for acquisitions, which lasted ~5 s, and then
instructed to resume breathing after the shear wave data were
saved. After the subject paused breathing, an imaging location
was found that had homogeneous liver parenchyma on standard
B-mode imaging, devoid of any vessels or other substructures
of the liver. The measurement was performed at a portion of the
liver that was at least 60 mm thick without large vessels. In the
ARFI elastography mode, the region of interest was placed
20–30 mm from the liver surface and the pushing pulse was
transmitted. The SWV from the liver tissue was calculated as the
median value of 10 successful acquisitions (m/s) in each patient.
2.2. Upper gastrointestinal endoscopy
All patients with ultrasound evidence of splenomegaly under-
went upper gastrointestinal endoscopy.
2.3. Statistical analyses
The Kolmogorov–Smirnov goodness of-fit test was applied for
determining whether sample data likely derive from a normally
distributed population. As data had a skewed distribution, they are
given as mean and 95% confidence intervals (CI). Counts and
percentages of affected patients are indicated. For between-group
differences in continuous variables, the Mann–Whitney U, the
Kruskal–Wallis or the χ2 test (2-sided) were used whenever
appropriate. Correlations analysis was performed using the
Spearman Rank Correlation coefficient.
Multivariate logistic regression, corrected for age, FEV1,
diagnosis of pancreatic insufficiency and/or diabetes mellitus,
was run to identify factors associated with CFLD. A backward
elimination approach was used to remove non significant
variables and to determine the most parsimonious model.
The receiver operating characteristic (ROC) analysis was run.
Areas under the ROC curve (AUC) with 95% CI were calculated
to assess the diagnostic accuracy for the detection of CFLD with
signs of PHT at ultrasonography only, as gastroscopy for the
detection of esophageal varices was not performed in all.
All statistical significance was taken at the 95% confidence
interval with significance set at pb0.05 for all the comparisons
and models. SPSS 15.0 for windows (SPSS Inc., Chicago, IL,
USA) was used.
3. Results
3.1. Patient characteristics and outcomes
Anthropometrics, clinical and laboratory parameters of the
study population are reported in Table 1. Patients were all-Caucasian and aged 14.4 years (95%CI 12.6–16.2). Nineteen
patients (25.3%) were Δf508 homozygous. Nine of them (12%)
had meconium ileus at birth. Thirteen patients (17%) presented
with cystic fibrosis related diabetes and 60 (80%) with
pancreatic insufficiency. No significant differences in anthro-
pometrics, clinical and laboratory parameters were observed
between groups of patients carrying different genotypes.
Patients with cystic fibrosis related diabetes did not differ
from those free of diabetes (data not shown). On the contrary,
patients with pancreatic insufficiency had slightly altered liver
function respect with pancreatic sufficient patients (ALT
31.45 IU/L, 95%CI 27.15–35.75 vs. 20.4, 95%CI 16.5–24.3;
p=0.001; albumin 4.20, 95CI% 4.10–4.3 vs. 4.4 mg/dl, 95%CI
4.10–4.30, p=0.06; γGT 29.8, 95%CI 18.5–41 vs. 11.0 IU/L,
95%CI 8.95–13; p=0.05).
3.2. Detection of liver disease
Twenty patients (28.1%) presented with altered liver
function tests above the normal threshold of 40 IU/L.
Ultrasound abnormalities of the hepatic parenchyma (Table 1)
were found in 61 patients (81%): 17 (23.6%) presented at least
Table 2
Shear wave velocity in patients presenting with pancreatic insufficiency and
signs of liver involvement.
Sign of pancreatic/liver
involvement
N Shear wave velocity (m/s) p
Pancreatic insufficiency 0=15 1.03 (0.93–1.13) 0.001
1=60 1.26 (1.18–1.34)
Altered liver function tests 0=55 1.15 (1.09–1.22) 0.004
1=20 1.40 (1.18–1.62)
Oesophageal varices 0=67 1.15 (1.09–1.21) b0.0001
1=8 1.62 (1.26–2.0)
Ultrasound score of CFLD b0.0001
0 16 0.97 (0.89–1.06)
1 14 1.07 (1.00–1.15)
2 23 1.17 (1.07–1.28)
3 16 1.33 (1.16–1.51)
4 6 1.68 (1.19–2.16)
Data are expressed as mean and 95%CI, counts of patients without (0) or with
[1] pancreatic insufficiency or sign of liver involvement. p represents the
statistical significance at the Mann–Whitney u-test or the Kruskal–Wallis test
as appropriate.
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Fig. 1. Box plots of SWV in patients with no cystic fibrosis liver disease (no
CFLD, N=16), CFLD with no signs of Portal HyperTension (PHT, N=28),
CFLD with signs of PHT (N=18) and oesophageal varices (N=8). At the
Bonferroni post-hoc test, significant differences were observed between patients
with no CFLD and those with CFLD and signs of PHT (p=0.038) or
oesophageal varices (pb0.0001); and between patients with no CFLD and overt
varices (pb0.0001).
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(20.8%) three of them and 6 (8.3%) patients presented with all
the ultrasound signs associated with CFLD.
No patient presented with portal vein thrombosis at the
Doppler imaging. Eight patients presented oesophageal varices at
endoscopy: of grade 2 in 7 patients and grade 3–4 in 1 patient.
Hence, based on clinical and ultrasound evidence of hepatic
involvement, patients were stratified in patients with no CFLD
(N=16), in patients with CFLD but no signs of PHT (N=23),
CFLD patients with signs of PHT (N=28) and CFLD with
oesophageal varices (N=8).
Patients with pancreatic insufficiency (N=60) had a higher
prevalence of CFLD than pancreatic sufficient patients. Indeed,
they exhibited more frequently a dishomogeneous hepatic
echotexture (p=0.008) and hepatic nodular margins (p=0.02).
Patients with pancreatic insufficiency (N=60) had also a higher
ultrasound score (p=0.005). Seven patients (11.7%) with
pancreatic insufficiency had no CFLD, 18 (30%) had CFLD
with no signs of PHT, 35 (58.3%) had CFLD and signs of PHT,
8 (13.3%) of them presenting esophageal varices (pb0.0001).
3.3. ARFI and shear wave velocities
Mean value of SWVwas 1.20, ranging from 0.71 to 2.59 m/s.
Velocities were statistically different in patients with and without
pancreatic insufficiency (p=0.001) and in those with or without
signs of liver involvement on ultrasound. Indeed, mean SWV
increased as ultrasound score of liver involvement augmented
(pb0.0001; Table 2). Median values of SWV differed also
significantly between the four groups of patients were with no
CFLD, with CFLD but no signs of PHT, with CFLD and signs of
PHT, and with oesophageal varices (pb0.0001, Fig. 1).
Poor to mild, but significant correlations were found
between SWV and levels of AST (ro=0.320, p=0.01), ALT
(ro=0.461, pb0.0001); γGT (ro=0.371, p=0.003); and INR
(ro=0.513, p=0.001).
3.4. Regression model
Serum albumin (β=−0.064), INR (β=0.262), BMI-z score
(β=0.235) and ultrasonografic score (β=0.178) entered a
linear regression model adjusted for age and FEV1 (R2=0.656,
p=0.001), with ALT predicting significantly ARFI (β=0.591;
p=0.001).
3.5. ROC analysis
SWV detected pancreatic insufficiency (AUC 0.749, 95%
CI 0.618 to 0.879, p=0.001) and CFLD with signs of PHT
(AUC 0.84, 95% CI 0.738 to 1.031, pb0.0001) with good
specificity and sensitivity.
4. Discussion
Here we report quantification of shear wave velocity in
patients with liver disease associated with cystic fibrosis.
Findings from our study suggest that ARFI is a reliable, non-invasive technique, potentially useful in the clinical follow-up
of such patients. As high are values of SWV, as high is the risk
to present severe liver involvement, namely portal hypertension
and oesophageal varices. Indeed, mean values of SWV were
significantly different in patients with simple CFLD respect to
those with CFLD and signs of portal hypertension (Fig. 1). In
keeping with these results, we recommend to perform the ARFI
in all the patients with cystic fibrosis and the endoscopy in
those with values of SWV in the upper limits.
Of note, patients with pancreatic insufficiency showed
increased values of mean SWV, which reflected a more severe
hepatic involvement as assessed by the ultrasonography. In
their report, Colombo et al. [1] found that CF patients with a
history of meconium ileus are 5 times as likely to develop
431M. Manco et al. / Journal of Cystic Fibrosis 11 (2012) 427–432CFLD as those without it. Alternatively, common genes may
render CF patients susceptible to fibrosis of both the hepatic
and the pancreatic parenchyma [19].
Results of the present study must be deemed as preliminary.
Indeed, several drawbacks affect the study. Our series was
restricted to patients suspected of having CFLD based on the
occurrence of at least one clinical, biochemical or ultrasound
criteria. This recruitment strategy may have introduced selection
bias in a general sample of FC patients. Hepatic involvement was
basically staged by using a simple and intuitive, but not validated
ultrasonographic score. On ultrasound, portal hypertension was
suspected on the basis of detection of irregular margins and a
nodular pattern, and not of more reliable means such as the
measurement of the hepatic venous pressure gradient. The sample
size of patients who underwent endoscopy was too small to
perform a ROC in order to identify a SWV cut-off value able to
predict oesophageal varices. Finally, we did not perform dual-
pass liver biopsy, which remains the gold standard technique for
staging hepatic fibrosis. Consequently, we could not investigate
the performance of SWV in detecting liver fibrosis. Neither, we
could assess the ability of SWV to the predict progression of the
liver disease.
To the best of our knowledge, performance of ARFI in
detecting fibrosis has been investigated in study of healthy adult
volunteers [20] and in patients affected by different hepatopathies
[7–15]. Average SWV has been found correlating with serum
markers of fibrosis (i.e. hyaluronic acid and type 4 collagen) [10].
Hence, the correlation between hepatic stiffness and fibrosis stage
has found a molecular correlate in studies demonstrating that the
physical properties of extra-cellular matrix affect activation of
hepatic stellate cells [21]..Importantly, increased stiffness may
actually precede fibrosis as result of both increased oedema and
inflammatory cell infiltration [22]. In patients with chronic
hepatitis C, SWVN1.34 m/s was diagnostic of moderate to
severe fibrosis (F score between 2 and 4), SWVN1.44 m/s of a
score between severe fibrosis and cirrhosis, and SWV N1.80 m/s
was diagnostic of cirrhosis (F4 grade) [10]. Similar results were
observed in a different study, which did not provide cut-off
values but mean values of SWV associated with increasing
grades of fibrosis [12]. In patients with fatty liver and no
histological evidence of fibrosis median value of SWV was
1.040 m/s. It increased from 1.120 m/s in those with mild fibrosis
(F1), to 1.130 m/s in moderate fibrosis (F2), 1.780 m/s in grade 3,
and 2.180 m/s for those with cirrhosis. The optimal cut-off values
of SWV for the diagnosis of hepatic fibrosis stages 3 and 4 were
1.77 m/s and 1.90 m/s, respectively [14].
Taken together, results from the above-refereed studies
support firmly the concept that there is a consistent gradual
increase of the risk of liver fibrosis as SWV increases. The
ARFI method is based on the ability of differentiating tissue
structure via a mechanical property (i.e. tissue rigidity) [23].
The liver is considered as a linear, isotropic, elastic body and
measured SWV is indicative of tissue rigidity of the whole
parenchyma [24]. Considering a median values of ten multiple
SWV estimates for each lobe, sampling error associated with
liver biopsies and artefacts due to cardiac motion are overcome.
Thus, a more accurate staging of average liver fibrosis may beprovided in those conditions such as CFLD, characterised by
focal involvement of hepatic parenchyma. As recommended
[7], measurements of SWV were done at the right lobe to avoid
interferences with cardiac and diaphragm motions. However, in
CFLD as more generally in any condition of cirrhosis, the right
lobe is expected to be atrophic as compared to the hypertrophic
left lobe. Serial measurements of SWV at the left lobe
correlated significantly but poorly (ro=0.392; p=0.004) with
median values at the right side. Such poor correlation might be
due either to motion interferences at the left lobe or to a
different parenchymal consistency of one lobe respect with the
other segments.
Relevant to the present study, measurement of SWV seems
independent of age and sex [20].
Liver stiffness as correlate of hepatic fibrosis has been
investigated also using a different technique, which is the
transient elastography [25,26]. Both the latter studies and our
investigation respond to the need for non-invasively staging of
hepatic fibrosis in CFLD. In their cohort study, Lewindon et al.
[3] demonstrated clearly that biopsy-proven liver fibrosis leads
to cirrhosis and PHT and accurately predicts progression of
liver disease. On the contrary, caution should be warranted in
interpreting ultrasound findings in patients with suspected
CFLD, particularly in the absence of liver nodularity and
splenomegaly or in presence of steatosis [3,27,28].5. Conclusions
ARFI may represent an easy, fast and non-invasive tool for
the clinical follow-up of patients with cystic fibrosis associated
liver disease. ARFI imaging may be useful to discern those
patients with advanced liver disease who deserve upper
endoscopy, and conversely, to spare patients the potential
complications of such procedure, thus reducing associated
health-care costs and resource utilization. Longitudinal studies
are needed to estimate ARFI performance in predicting and
monitoring progression of hepatic disease, and particularly, in
detecting early liver fibrosis.
Furthermore, data from the present investigation confirm the
results of previous studies [3], which found that clinical
evaluation and levels of serum aminotransferases, despite
continued widespread clinical practice, may be non specific
for the detection of advanced liver disease.Conﬂict of interest
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